教授/研究员
您的当前位置:首页  师资队伍  员工名录  教授/研究员
廖晨钟
发布时间:2018-09-14    阅读次数: 4263

姓 名:
廖晨钟
职 称:
教授
职 务:

所属系:
药物科学与工程系
邮 箱:
czliao@hfut.edu.cn
电 话:
182-5600-7962
个人学习工作简介
 工作经历

²2012/10-至今,合肥工业大学,生物与医学工程学院,教授

²2010/10-2012/9University of MichiganMedical SchoolResearch Scientist

²2005/10-2010/9National Institutes of HealthNational Cancer Institute,博士后

²2004/7-2005/8,深圳微芯生物科技有限责任公司,生化信息学部,主任

²1998/7-2001/8,北京工业大学出版社,图书编辑

教育经历

²2001/92004/7,中国科学院,博士

²1995/91998/6,北京工业大学,硕士

²1991/91995/7,青岛科技大学,学士

研究兴趣领域

药物设计、药物合成、新药研发、化学信息学

1、药物设计与合成

2、计算机辅助药物设计
3、化学信息学
4、恶性肿瘤药物、神经退行性疾病药物、抗艾滋病药物的研发
社会兼职

²安徽省药学会第九届理事会理事

²安徽省药学会药物化学专业委员会副主任委员

²美国国家健康研究院癌症研究所(National Institutes of Health, National Cancer Institute)客座研究员(Guest Researcher

²美国化学会(American Chemical Society)会员

²美国癌症研究协会(American Association for Cancer Research)会员

²多家国际知名杂志,如ACS Medicinal Chemistry Letters, Journal of Medicinal Chemistry, Journal of Chemical Information and Modeling, Future Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, Bioorganic & Medicinal Chemistry, Antiviral Research, Journal of Chemical Theory and Computation, Current Topics in Medicinal Chemistry, Current Medicinal Chemistry, PLoS Computational Biology, Molecular Informatics, Letters in Drug Design & Discovery, Journal of Biophysics and Structural Biology等的特约审稿人

²香港特区政府总部食物及卫生局科研基金的特约评审人

²担任Current Topics in Medicinal Chemistry杂志的Guest Editor,主编过一期特刊《Current Progress in the Development of Metalloprotein Inhibitors

个人业绩成果

²学术业绩:Drug Discovery TodayJournal of Medicinal ChemistryACS Medicinal Chemistry LettersJournal of Chemical Information and Modeling等药学、药物化学主流国际期刊发表高质量论文70余篇;参与3部国际学术专著的编写工作;申请国际国内专利10余项;为多个国际知名期刊的审稿人。

²教育业绩:成功为合肥工业大学申办药学本科专业及药学专业硕士点;参与教材《药物设计学》的编写;指导的国家级大学生创新训练项目获得优秀成绩;指导的本科毕业论文多次获得优秀成绩;被聘为合肥工业大学百名优秀创新创业导师;担任本科生《专业导论》、《药物化学》、《药物设计学》及研究生《计算机辅助药物设计》、《高等药物化学》等多门课程的教学工作。

²产业业绩:在深圳微芯生物科技有限责任公司担任生化信息学部主任期间,设计的抗2型糖尿病药物西格列他钠作为国家1.1类新药已进入临床III期研究,参与设计的抗恶性肿瘤药物西达本胺作为国家1.1类新药已获国家CFDA批准,用于治疗复发或难治性外周T细胞淋巴瘤。

目前承担的科研项目

²《共价/非共价Polo-like Kinase 2抑制剂的设计、合成及其抗帕金森氏症的机理研究》,国家自然科学基金面上项目,项目批准号:216720502017/01 – 2020/1265万元,在研,主持

²《选择性识别端粒蛋白p65的苯并吡喃新先导:优化设计合成及作用机制》,国家自然科学基金面上项目,项目批准号:215720032016/01 – 2019/1265万元,在研,参加

²《基于结构的髓样细胞白血病-1抑制剂设计、结构优化及抗肿瘤活性研究》,合肥工业大学春华计划(中央高校基本科研业务费专项资金资助),编号:2013HGCH00152013/05 – 2014/1230万元,主持

²合肥工业大学人才引进基金

专著论文专利

发表的期刊论文

1Developing Polo-Like Kinase 1 Inhibitors. Future Medicinal Chemistry, 2020, 12, 869-871.(通讯作者)

2Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters, 2020, 30, 127036.(通讯作者)

3Discovery and development of plasma kallikrein inhibitors for multiple diseases. European Journal of Medicinal Chemistry, 2020,190, 112137.(通讯作者)

4Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library. European Journal of Medicinal Chemistry, 2020,189, 112023.

5Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins. Journal of Medicinal Chemistry, 2020,63, 2489-2510.

6LongShengZhi Capsule Inhibits Doxorubicin-Induced Heart Failure by Anti-Oxidative Stress. Biomedicine & Pharmacother, 2020, 123, 109803.

7Discovery of Class I Histone Deacetylase Inhibitors Based on Romidpesin With Promising Selectivity for Cancer Cells. Future Medicinal Chemistry, 2020, 12, 311-323.

8Structure-based Design and SAR Development of Novel Selective Polo-Like Kinase 1 Inhibitors Having the Tetrahydropteridin Scaffold. European Journal of Medicinal Chemistry, 2019, 184, 111769.(通讯作者)

9Developments in Inhibiting Platelet Aggregation Based on Different Design Strategies. Future Medicinal Chemistry, 2019, 11, 1757-1775.(通讯作者)

10Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors. Current Medicinal Chemistry, 2019, DOI: 10.2174/0929867326666190402110528.

11Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure. Bioorganic & Medicinal Chemistry Letters, 2019, 29, 1012-1018.(通讯作者)

12Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors. Bioorganic & Medicinal Chemistry Letters, 2019, 29, 1090-1093.(通讯作者)

13Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening. Scientific Reports, 2018, 8, 10210.(并列第一作者)

14The selectivity and bioavailability improvement of novel oral anticoagulants: An overview. European Journal of Medicinal Chemistry, 2018,146, 299-317.通讯作者

15Design, Synthesis and Bioevalucation of Novel 2,3-Dihydro-1H-inden-1-amine Derivatives as Potent and Selective Human Monoamine Oxidase B Inhibitors Based on Rasagiline. European Journal of Medicinal Chemistry, 2018,145, 588-593.通讯作者

16Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold. European Journal of Medicinal Chemistry, 2018,143, 724-731.通讯作者

17、甲氨蝶呤缓释植入剂延迟小鼠肉瘤复发的研究. 中国新药杂志, 2017, 26, 2828-3834.通讯作者

18Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer. Current Medicinal Chemistry,2017, 24, 4166-4179.通讯作者

19nhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain. ACS Chemical Biology. 2017, 12, 724-734.

20Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities. Journal of Medicinal Chemistry, 2016, 59, 5766-5779.并列第一作者

21From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discovery Today, 2016, 21, 1027-1036.通讯作者

22Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors. Bioorganic & Medicinal Chemistry,2016, 24, 1741-1748.通讯作者

23Identification of human telomerase inhibitors having the core of N-acyl-4,5-dihydropyrazole with anticancer effects. Bioorganic & Medicinal Chemistry Letters,2016, 26, 1508-1511.通讯作者

24Chemical Structure Similarity Search for Ligand-Based Virtual Screening: Methods and Computational Resources. Current Drug Targets. 2016, 17, 1580 - 1585.

25Perspectives in Medicinal Chemistry: Metalloprotein Inhibitors: What Have We Made and What is the Next Step? Current Topics in Medicinal Chemistry. 2016, 16, 467-469.通讯作者

26Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in vitro and in vivo Antitumor Activities. Journal of Medicinal Chemistry, 2015, 58, 7672-7680.

27Metalloprotein Inhibitors for the Treatment of Human Diseases. Current Topics in Medicinal Chemistry, 2016, 16, 384-396.通讯作者

28Editorial: Current Progress in the Development of Metalloprotein Inhibitors. Current Topics in Medicinal Chemistry, 2016, 16, 383.通讯作者

29Novel HIV-1 Integrase Inhibitor Development by Virtual Screening Based on QSAR Models. Current Topics in Medicinal Chemistry, 2016, 16, 441-448.

30Ma N, Luo Y, Wang Y, Liao C, Ye WC, Jiang S. Selective histone deacetylase inhibitors with anticancer activity. Current Topics in Medicinal Chemistry, 2016, 16, 415-426.

31Novel 2H-chromen-2-one Derivatives of Resveratrol: Design, Synthesis, Modeling and Use as Human Monoamine Oxidase Inhibitors. European Journal of Medicinal Chemistry, 2015,103, 185-190.通讯作者

32Synthesis, Characterization and Antitumor Activity of Novel Ferrocene-Based Amides Bearing Pyrazolyl Moiety. Journal of Inorganic and Organometallic Polymers and Materials, 2015, 25, 419-426.

33Discovery and Pharmacophore Studies of Novel Pyrazole-Based Anti-Melanoma Agents. CHEMISTRY & BIODIVERSITY, 2015, 12, 116-132.通讯作者

34、药物分子设计中的大数据问题. 科学通报, 2015, 60, 558-565.

35Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. European Journal of Medicinal Chemistry, 2014, 86, 639-652.并列第一作者

363-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.Journal of Medicinal Chemistry, 2014. 57, 4111-4133.

37A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Molecular Cancer Therapeutics, 2014, 13, 565-575.并列第一作者

38Diversity evolution and jump of Polo-like kinase 1 inhibitors. Science China Chemistry, 2013, 56, 1392-1401.通讯作者

39Biological evaluation of 2-methylpyrimidine derivatives as active pan Bcr-Abl inhibitors. Science China Chemistry, 2014, 57, 823-832.

40Targeting recruitment of Disruptor Of Telomeric silencing 1-Like (DOT1L): Characterizing the interactions between DOT1L and MLL-fusion proteins. Journal of Biological Chemistry, 2013, 288, 30585-30596.

41PDB Ligand Conformational Energies Calculated Quantum-Mechanically. Journal of Chemical Information and Modeling, 2012, 52, 739-756.

42Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opinion on Therapeutic Patents, 2012,22, 37-55.

43Software and Resources for Computational Medicinal Chemistry. Future Medicinal Chemistry, 2011, 3, 1123-1140.(第一作者通讯作者

44Discovery of a Novel Hybrid from Finasteride and Epristeride as 5α-reductase Inhibitor. Bioorganic & Medicinal Chemistry Letters, 2011, 21, 475-478.通讯作者

45Probing Binding Modes of Small Molecule Inhibitors to the Polo-Box Domain of Human Polo-like Kinase 1. ACS Medicinal Chemistry Letters, 2010, 1, 110-114.(第一作者

46Computer Tools in the Discovery of HIV-1 Integrase Inhibitors. Future Medicinal Chemistry, 2010, 2, 1123-1140.(第一作者

47Authentic HIV-1 Integrase Inhibitors. Future Medicinal Chemistry, 2010, 2, 1107-1122.(第一作者

48Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells. Organic Letters, 2010, 12, 1368-1371.

49Tautomerism and Magnesium Chelation of HIV-1 Integrase Inhibitors: A Theoretical Study. ChemMedChem, 2010, 5, 1053-1066.(第一作者

50Polo-box domain: A Versatile Mediator of Polo-like Kinase Function. Cellular and Molecular Life Sciences, 2010, 67, 1957-1970.

51Comparison of Nine Programs Predicting pKa Values of Pharmaceutical Substances. Journal of Chemical Information and Modeling, 2009,49,2801–2812.(第一作者

52Computer-assisted search and optimization of new human immunodeficiency virus integrase inhibitors. Biomeditsinskaya Khimiya (Biomedical Chemistry), 2009, 55, 544-557.

53Structural and functional analyses of a minimal phosphopeptide targeting the polo-box domain of polo-like kinase 1. Nature Structural & Molecular Biology, 2009, 16, 876-883.

54Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. Bioorganic & Medicinal Chemistry Letters, 2009, 19, 2693-2698.

55Synthesis and conformational analysis of locked carbocyclic analogues of 1,3-diazepinone riboside, a high-affinity cytidine deaminase inhibitor. Journal of Organic Chemistry, 2009, 74, 6212-6223.

56The Nucleoside Analog D-carba T Blocks HIV-1 Reverse Transcription. Journal of Medicinal Chemistry, 2009, 52, 5356-5364.

57D-(+)-iso-Methanocarbathymidine, a high affinity substrate for herpes simplex virus 1 thymidine kinase. ChemMedChem, 2008, 3, 1129-1134.

58Virtual screening application of a model of full-length HIV-1 integrase complexed with viral DNA. Bioorganic & Medicinal Chemistry Letters. 2007, 17, 5361-5365.(第一作者

59Sculpting the bicyclo[3.1.0]hexane template of carbocyclic nucleosides to improve recognition by herpes thymidine kinase. Journal of the American Chemical Society, 2007, 129, 6216-6222.

60Biotinylated biphenyl ketone-containing 2,4-dioxobutanoic acids designed as HIV-1 integrase photoaffinity ligands. Bioorganic & Medicinal Chemistry, 2006, 14, 7816-7825.

61A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice. Biological & Pharmaceutical Bulletin, 2005, 28, 1192-1196.

62Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators. European Journal of Medicinal Chemistry, 2005, 40, 632-640.(第一作者,通讯作者)

63Design, synthesis and evaluation of novel noncyclic 1,3-dicarbonyl compounds as PPARα selective activators. Bioorganic & Medicinal Chemistry Letters. 2004, 14, 3507-3511.(并列第一作者)

64Eigen value analysis of peroxisome proliferator-activated receptor γ agonists. Journal of Chemical Information and Computer Sciences. 2004, 44, 230-238.(第一作者

653D QSAR studies on peroxisome proliferator-activated receptor γ agonists using CoMFA and CoMSIA. Journal of Molecular Modeling. 2004, 10, 165-177.(第一作者

66Quantitative structure-activity relationship study of histone deacetylase inhibitors. Current Medicinal Chemistry Anti-Cancer Agents. 2004, 4, 273-299.

67Quantitative structure-activity relationship study of bisphosphonates. Internet Electronic Journal of Molecular Design. 2004, 3, 622-650.

683D-QSAR of Sulfonamide Hydroxamic Acid HDAC Inhibitors. Acta Phys. – Chim. Sin. (Wuli Huaxue Xuebao).2005, 21, 333-337.

69Docking study of HDAC: implication for benzamide inhibitors binding mode. Acta Phys. – Chim. Sin. (Wuli Huaxue Xuebao). 2004, 20, 569-572.

70、一种用SMILES码构建虚拟组合化学库的新方法. 计算机与应用化学2005, 22, 247-252.(第一作者

71、新型胰岛素增敏剂西格列羧的合成. 中国新药杂志2004, 13, 718-720.

72、新型抗肿瘤组蛋白去乙酰化酶抑制剂西达本胺的合成. 中国新药杂志2004, 13, 536-538.

73、生化信息学在药物创新过程中的重要作用. 中国新药杂志2004, 13, 385-388.

74、以PPAR为靶标的抗2型糖尿病药物研发策略. 中国新药杂志2003, 12, 980-983.(第一作者

75、基于甲骨文数据库管理系统的化学结构检索数据库的设计与实现. 计算机与应用化学2003, 20, 556-562.

参编学术专著及教材

1、《药物设计学》,中国医药科技出版社,2016.

2Molecular docking and structure-based virtual screening. In “In Silico Drug Discovery and Design Techniques”. (ISBN: 978-1-909453-02-9). Invited book chapter, Future Science Group, 2013, 7-22.

3HIV-1 integrase-DNA models. In “HIV-1 Integrase: Mechanism of Action and Inhibitor Design”. Invited book chapter, John Wiley & Sons, Inc. 2011, 429-455.

4An integrated biochemoinformatics system for drug discovery: managing and mining chemical structure information, biological activity fingerprints, and gene expression profiling patterns. In “Frontiers of Biochip Technologies”, Xing WL and Cheng J (Editors), Springer US, Invited book chapter, 2006, 191-206.

版权所有:合肥工业大学食品与生物工程学院  技术支持:南京苏迪
地址:安徽省合肥市经济技术开发区大学城翡翠路420号  邮编:230601  电话:0551-62901285  邮箱:spxy@hfut.edu.cn
皖ICP备12146036号-1  您是本站第
访客!
触碰右侧展开